Camilla Muccini

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine.

Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine.

Journal: AIDS care

Published: September 07, 2026

Hepatitis B Reactivation in People with HIV After Switching to a 2-Drug Anti-HBV Sparing Regimen.

Hepatitis B Reactivation in People with HIV After Switching to a 2-Drug Anti-HBV Sparing Regimen.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: June 22, 2026

Virological outcomes of PWH who discontinued cabotegravir/rilpivirine long-acting therapy in a real-world context.

Virological outcomes of PWH who discontinued cabotegravir/rilpivirine long-acting therapy in a real-world context.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: March 04, 2026

Highlighting advances on clinical management of pediatric HIV.

Highlighting advances on clinical management of pediatric HIV.

Journal: Expert opinion on pharmacotherapy

Published: February 25, 2026

The Role of Immune Dysregulation Markers in Cardiovascular Risk of People Living with HIV: Association Among Intima Media Changes, CD4/CD8 Ratio, and CD4+ Cell Count Nadir.

The Role of Immune Dysregulation Markers in Cardiovascular Risk of People Living with HIV: Association Among Intima Media Changes, CD4/CD8 Ratio, and CD4+ Cell Count Nadir.

Journal: Viruses

Published: February 21, 2026

Two-year efficacy and safety of long-acting cabotegravir and rilpivirine in the SCohoLART study.

Two-year efficacy and safety of long-acting cabotegravir and rilpivirine in the SCohoLART study.

Journal: AIDS (London, England)

Published: February 19, 2026

Evaluating long-acting injectable HIV treatment: an update on cabotegravir and rilpivirine.

Evaluating long-acting injectable HIV treatment: an update on cabotegravir and rilpivirine.

Journal: Expert review of anti-infective therapy

Published: January 08, 2026

Routine HIV RNA Testing During Injectable Cabotegravir and Oral Preexposure Prophylaxis Use.

Routine HIV RNA Testing During Injectable Cabotegravir and Oral Preexposure Prophylaxis Use.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 17, 2025

Peer-supported digital collection of patient-reported outcomes in HIV care: Promise, practical barriers and lessons from a pilot study within the ICONA cohort.

Peer-supported digital collection of patient-reported outcomes in HIV care: Promise, practical barriers and lessons from a pilot study within the ICONA cohort.

Journal: HIV medicine

Published: November 26, 2025

PROs Assessment in Dual (Either Oral or Injectable) Antiretroviral Regimen in People with HIV: A Narrative Review.

PROs Assessment in Dual (Either Oral or Injectable) Antiretroviral Regimen in People with HIV: A Narrative Review.

Journal: Viruses

Published: November 23, 2025

Achieving reimbursable PrEP is insufficient to increase and diversify the users attending community-based services.

Achieving reimbursable PrEP is insufficient to increase and diversify the users attending community-based services.

Journal: HIV medicine

Published: November 02, 2025

Medical and psychological needs for injectable long-acting cabotegravir as pre-exposure prophylaxis.

Medical and psychological needs for injectable long-acting cabotegravir as pre-exposure prophylaxis.

Journal: Sexually transmitted infections

Published: October 07, 2025

Showing 1-12 of 90

Last Updated: 09/26/2026